- Conditions
- Urothelial/Bladder Cancer, Nos
- Interventions
- Atezolizumab, PGV001, Poly ICLC, Normal saline
- Drug · Biological
- Lead sponsor
- Matthew Galsky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 512
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Breast Cancer
- Interventions
- Atezolizumab, Trastuzumab emtansine, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 15
- States / cities
- Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 12 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Cyclophosphamide, Fludarabine, MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells, PD1 Inhibitor
- Drug · Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer
- Interventions
- CJRB-101, Pembrolizumab injection
- Drug
- Lead sponsor
- CJ Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Irvine, California • Pittsburgh, Pennsylvania
- Conditions
- Malignant Melanoma
- Interventions
- Atezolizumab, Cobimetinib
- Biological · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Detroit, Michigan + 3 more
- Conditions
- Cervical Cancer, Cervical Cancer Recurrent, Cervical Cancer Metastatic
- Interventions
- Stereotactic body radiation therapy (SBRT), Atezolizumab
- Radiation · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Hilliard, Ohio
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Atezolizumab, Ipatasertib, Paclitaxel, Placebo for Atezolizumab, Placebo for Ipatasertib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 31
- States / cities
- Mobile, Alabama • Springdale, Arkansas • Los Angeles, California + 25 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Atezolizumab, Radiation Therapy, Temozolomide
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Extensive Stage Lung Small Cell Carcinoma
- Interventions
- Atezolizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy
- Drug · Procedure · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 411
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 296 more
- Conditions
- Stage II Melanoma
- Interventions
- Atezolizumab, Tiragolumab, Signatera Assay
- Drug · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Extensive-stage Small-cell Lung Cancer, Liver Metastases
- Interventions
- Bevacizumab
- Drug
- Lead sponsor
- Kamya Sankar
- Other
- Eligibility
- Not listed
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Ann Arbor, Michigan
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Biospecimen Collection, Cemiplimab, Computed Tomography, Diclofenac Potassium, Electronic Health Record Review, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Positron Emission Tomography
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab, Docetaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 59
- States / cities
- Bakersfield, California • Burbank, California • Fullerton, California + 54 more
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Atezolizumab, CXCR1/2 Inhibitor SX-682, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Biopsy Procedure
- Biological · Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- Abemaciclib 200 MG, Atezolizumab 1200 MG in 20 ML Injection, Abemaciclib 150 MG
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 1 more
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- RO7496353, Atezolizumab, Capecitabine, S-1, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania
- Conditions
- Gastric Adenocarcinoma
- Interventions
- Derazantinib, Derazantinib-paclitaxel-ramucirumab combination
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Orlando, Florida • New York, New York
- Conditions
- Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
- Interventions
- Cytokine Induced Memory-Like Natural Killer Cells, Atezolizumb, CIML-NK cell therapy
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8, Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8
- Interventions
- Atezolizumab, Bevacizumab, Therapeutic Conventional Surgery
- Biological · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Endometrial Cancer
- Interventions
- Bevacizumab, Atezolizumab
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • St Louis, Missouri • Oklahoma City, Oklahoma
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin, Cyclophosphamide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 17
- States / cities
- Concord, California • Los Angeles, California • St. Helena, California + 14 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Atezolizumab and Recombinant Human Hyaluronidase, Survey Administration
- Biological · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Bladder Cancer
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 35 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine, Pemetrexed
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 45
- States / cities
- Fayetteville, Arkansas • Encinitas, California • Fountain Valley, California + 38 more